What question did this study set out to answer?

The aim is to evaluate recent advancements in eczema therapeutics and the multifaceted challenges they pose, particularly in pediatric patients.

March 23, 2026Open Access

Eczema therapeutics- Gains and challenges

Key Points

The aim is to evaluate recent advancements in eczema therapeutics and the multifaceted challenges they pose, particularly in pediatric patients.
Review of recent literature on treatments for eczema and atopic dermatitis.
Discussion of the impact of diet and adverse effects of therapies.
Exploration of the neurogenic and gut-skin axes in skin inflammation.
Recent targeted therapies, especially JAK inhibitors, show promise in managing eczema.
Challenges include managing psychosocial impacts on families and the adverse effects of prolonged treatments.
Emerging evidence on the influence of diet and gut health on skin conditions is highlighted.

Abstract

There have been rapid gains in the field of therapeutics in dermatology over the past decade.As we move past the era of generalized topical or systemic immunomodulators and as a paradigm shift evaluate targeted treatment, it hopefully heralds the era of personalized medicine.However, effective management of a chronic, visible dermatosis necessitates consideration of diverse requirements beyond just drug therapy.This is further complicated by the onset of atopic eczema in the pediatric age group, which results in an adverse impact not only on the patient but also has a psychosocial negative impact on the family.Further, concerns include apprehensions about the impact of diet and of local and systemic adverse effects attributable to the prolonged treatment.We continue with the symposium focused on pediatric eczemas with Dr. Maitreyee Panda as the guest editor.In these two articles, authors explore the impact of diet and provide an update on topical therapies in eczema, from traditional to recent options.We sincerely hope that these symposia articles will provide the readers with an updated source of information on the management of pediatric eczemas. 1,2t present, the spotlight in inflammatory dermatoses therapy is on Janus Kinase (JAK) inhibitors, drugs that cause immunomodulation by targeting the JAK-signal transducer and activator of transcription signaling pathway.This issue includes focused reviews on the role of ruxolitinib and upadacitinib in our therapeutic armamentarium, and the authors report real-world experience on the off-label use of tofacitinib and abrocitinib in the management of adult atopic dermatitis and prurigo nodularis, respectively. 345]6 A similar profound adverse impact on patients' quality of life is evident while managing chronic urticaria.Therefore, it is pertinent to delve into the mind-skin (neurogenic inflammation) and gut-skin (dysbiosis and inflammation) axis.In this issue, Farouk and Abdullah explore the concept of neurogenic inflammation in chronic urticaria and delineate its implications in clinical management, and also outline future research areas.

AI에게 질문

Bookmark

View Full Paper